LRMR רווח נקי למניה ב-12 החודשים האחרונים Larimar Therapeutics, Inc.

Larimar Therapeutics (LRMR) TTM net income per share demonstrates the impact of optimized distribution of neurological agents through partner laboratories, while the -1.99 mark reflects the latest data. However, high capital requirements and the risk of clinical trial failure for the Friedreich's ataxia drug create instability. The environmental profile is limited solely to compliance with chemical disposal regulations at research centers.

The development of Friedreich's ataxia therapy via the drug Nomlabofusp defines the capital expenditure profile of Larimar Therapeutics (LRMR), where the rolling annual earnings per share visualize the efficiency of innovation monetization. This metric aggregates annual net income distributed per share, allowing investors to assess the real profitability of the business regardless of capital dilution and to recognize stagnation in fundamental value in a timely manner.